Inhibrx Biosciences Inc. stocks have been trading up by 37.71 percent following highly positive biotech pipeline progress news
Key Takeaways
- Updated ozekibart plus FOLFIRI data in metastatic colorectal cancer showed a 20% objective response rate, 5.5‑month median PFS, 87% disease control, and manageable safety in heavily pretreated patients.
- The company plans an FDA meeting in 2026/07 to launch a first‑line registrational colorectal cancer trial and is pursuing accelerated pathways in late‑line colorectal cancer and refractory Ewing sarcoma.
- A Biologics License Application for ozekibart in conventional chondrosarcoma is already filed after a positive registrational trial.
- Stifel started coverage on INBX with a Buy rating and a $150 price target, flagging strong clinical progress for ozekibart and INBRX‑106 and a clear immuno‑oncology strategy.
Live Update At 10:02:50 EDT: On Wednesday, April 22, 2026 Inhibrx Biosciences Inc. stock [NASDAQ: INBX] is trending up by 37.71%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
INBX has been trading like a biotech rocket with loose bolts. Over the last few weeks, Inhibrx Biosciences Inc. ran from $58.88 on 2026/03/30 to a high of $155.29 on 2026/04/22 before closing that day at $115.79. That’s a massive range, and traders need to respect it.
The daily chart shows INBX grinding higher from the low $60s into the $80–$90 zone, then exploding into the $150s on the latest ozekibart headlines. Intraday, the 5‑minute tape tells the real story: a huge gap from the high $80s/low $90s to $147.50 at the open, a spike to $155.29, and then heavy selling down toward the mid‑$110s. INBX is clearly a momentum name where late chasers risk getting stuffed.
More Breaking News
- CMCSA Stock Grinds Higher As Earnings Beat Meets Big Restructure
- CMCSA Rallies As Earnings Beat Collides With Restructuring Overhang
- WKHS Stock Draws Traders As EV Orders Grow And AI Pivot Emerges
- WFF Stock Plunges Then Bases As Volatility Grips Chart
Under the hood, Inhibrx Biosciences is still a classic development‑stage biotech. Revenue is only about $1.3M, yet the enterprise value sits around $1.21B. That translates to a price‑to‑sales ratio above 900 and a price‑to‑book near 150. Profitability metrics are deep in the red, with negative EBITDA, heavy R&D spend, and free cash flow around ‑$30M last quarter. The balance sheet, though, shows roughly $124M in cash and a current ratio near 3.9, giving INBX some runway to keep funding its pipeline. For traders, this is a story stock, not a value play.
Why Traders Are Watching INBX Now
Traders are locking in on INBX because the story is finally lining up with the chart. Inhibrx Biosciences reported updated Phase 1/2 data for ozekibart (INBRX‑109) plus FOLFIRI in heavily pretreated metastatic colorectal cancer. These are tough patients who have usually burned through multiple standard therapies. In that setting, a 20% objective response rate and 87% disease control is not noise; it’s signal.
The median progression‑free survival of 5.5 months, paired with a manageable safety profile, gives INBX something the market can model. This is why you’re seeing those wide intraday swings — traders are trying to price in what late‑stage colorectal cancer and chondrosarcoma revenue could look like if these programs clear regulators.
On the regulatory front, INBX is moving from “maybe someday” to concrete timelines. The company plans an FDA meeting in the second half of 2026 to initiate a first‑line registrational colorectal cancer trial with ozekibart. At the same time, Inhibrx Biosciences is exploring accelerated pathways in fourth‑line colorectal cancer and refractory Ewing sarcoma, stacking potential shots on goal. And for conventional chondrosarcoma, the Biologics License Application for ozekibart is already in, backed by a positive registrational trial.
Layer on top the Stifel call: a fresh Buy rating on INBX with a $150 price target. That’s not just a number; it’s a clear message from the Street that the current pipeline — especially ozekibart and INBRX‑106 — justifies a premium story. Bullish coverage like this often pulls in new trading volume and can amplify every headline, good or bad. For active traders, INBX has all the ingredients: clinical catalysts, analyst validation, and serious volatility.
Conclusion
INBX is shaping up as a classic high‑risk, high‑reward biotech trade. Inhibrx Biosciences now has multiple late‑stage angles with ozekibart: metastatic colorectal cancer, potential accelerated paths in later‑line settings and Ewing sarcoma, plus a pending BLA in conventional chondrosarcoma. That stack of catalysts explains why INBX ripped into the $150s before pulling back. The market is no longer guessing whether the science works at all; it’s debating how big and how fast.
Financially, INBX is not a steady compounder. It’s burning cash, posting deep operating losses, and trading at extreme valuation multiples. The offset is that Inhibrx Biosciences holds over $120M in cash and a pipeline that the Street — including Stifel with its $150 target — is taking seriously. Traders need to remember that in names like INBX, sentiment can flip quickly on any data update or FDA feedback.
For short‑term trading, that means clear rules, hard stops, and no marrying the stock. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” The intraday tape already showed what happens when momentum turns — $40 swings in a single session. The opportunity is real, but so is the risk. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your discipline, so protect yourself first and always cut losses quickly.” INBX fits that rule perfectly: a powerful story for traders who stay nimble, prepared, and brutally honest with their risk.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.